glp-1 patent Ozempic, Wegovy and Rybelsus: The patents behind Novo Nordisk's weight-loss drugs Ozempic's Patent Protection Starts to

Enter the Dual and Triple Agonists To break through this ceiling, scientists began combining hormone targets: Dual Agonists (GLP-1 + GIP): Tirzepatide (Mounjaro, Zepbound) was the first commercially approved dual agonist

The SEMALEAN trial found lean mass declined then stabilised while handgrip strength improved by 4.5 kg and sarcopenic obesity prevalence fell from 49% to 33% over twelve months

A steady, protocol-driven titration gives the body time to adapt at each level and produces better long-term adherence and results

An oral semaglutide tablet for weight loss ( Wegovy pill ) may be approved soon

cold intolerance or feeling cold even in warm environments, suggesting metabolic slowdown